Search

Your search keyword '"Caimi, Paolo"' showing total 1,282 results
Start Over Author "Caimi, Paolo"
1,282 results on '"Caimi, Paolo"'

1. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation

Author

Epperla, Narendranath, Huang, Ying, Cashen, Amanda F., Vaughn, John L., Hanel, Walter, Badar, Talha, Barta, Stefan K., Caimi, Paolo F., Sethi, Tarsheen K., Reddy, Nishitha, Karmali, Reem, Bello, Celeste, Chavez, Julio C., Kothari, Shalin K., Hernandez-Ilizaliturri, Francisco J., Svoboda, Jakub, Lansigan, Frederick, Glenn, Martha J., Cohen, Jonathon B., Sorge, Caryn, Christian, Beth, Herrera, Alex F., Hamadani, Mehdi, Costa, Luciano J., and Xavier, Ana C.

Published
2024
Full Text
View/download PDF

3. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Author

Smith, Mitchell R., Jegede, Opeyemi A., Martin, Peter, Till, Brian G., Parekh, Samir S., Yang, David T., Hsi, Eric D., Witzig, Thomas, Dave, Sandeep, Scott, David, Hanson, Curtis, Kostakoglu Shields, Lale, Abdel-Samad, Nizar, Casulo, Carla, Bartlett, Nancy L., Caimi, Paolo F., Al Baghdadi, Tareq, Blum, Kristie A., Romer, Mark D., Inwards, David J., Lerner, Rachel E., Wagner, Lynne I., Little, Richard F., Friedberg, Jonathan W., Leonard, John P., and Kahl, Brad S.

Published
2024
Full Text
View/download PDF

4. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool

Author

Brem, Elizabeth A, Li, Hongli, Beaven, Anne W, Caimi, Paolo F, Cerchietti, Leandro, Alizadeh, Ash A, Olin, Rebecca, Henry, N Lynn, Dillon, Hildy, Little, Richard F, Laubach, Cara, LeBlanc, Michael, Friedberg, Jonathan W, and Smith, Sonali M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Hematology, Lymphoma, Clinical Trials and Supportive Activities, Aging, Rare Diseases, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Frailty, Humans, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Prospective Studies, Rituximab, DLBCL, Geriatric, Older, ctDNA, Oncology and carcinogenesis
Abstract

Diffuse large B cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy; however, cure is highly dependent on the ability to deliver intensive, anthracycline-based chemoimmunotherapy. Nearly one third of cases of DLBCL occur in patients over age 75 years, and advanced age is an important adverse feature in prognostic models. Despite this incidence in older patients, there is no clear accepted standard of care due to under-representation of this group in large randomized clinical trials. Furthermore, insufficient assessments of baseline frailty and prediction of toxicity hamper clinical decision-making. Here, we present an ongoing randomized study of R-miniCHOP chemoimmunotherapy with or without oral azacitidine (CC-486, Onureg) for patients age 75 and older with newly diagnosed DLBCL and associated aggressive lymphomas. The incorporation of an oral hypomethylating agent is based on increased tumor methylation as a biologic feature of older patients with DLBCL and a desire to minimize the injection burden for this population. This is the first randomized study in this population conducted in North America by the National Clinical Trials Network (NCTN) and will enroll up to 422 patients including 40 patients in a safety run-in phase. This study incorporates an objective assessment of baseline frailty (the FIL Tool) and a serial comprehensive geriatric assessment (CGA). Key correlative tests will include circulating tumor DNA (ctDNA) assays at pre-specified timepoints to explore if ctDNA quantity and methylation patterns correlate with response. S1918 has the potential to impact future trial design and to change the standard of care for patients 75 years and older with aggressive lymphoma given its randomized design, prospective incorporation of geriatric assessments, and exploration of ctDNA correlatives. Trial registration: The trial is registered with ClinicalTrial.gov Identifier NCT04799275.

Published
2022

5. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

Author

Metheny, Leland L., Sobecks, Ronald, Cho, Christina, Fu, Pingfu, Margevicius, Seunghee, Wang, Jiasheng, Ciarrone, Lisa, Kopp, Shelby, Convents, Robin D., Majhail, Navneet, Caimi, Paolo F., Otegbeye, Folashade, Cooper, Brenda W., Gallogly, Molly, Malek, Ehsan, Tomlinson, Benjamin, Gerds, Aaron T., Hamilton, Betty, Giralt, Sergio, Perales, Miguel-Angel, and de Lima, Marcos

Published
2024
Full Text
View/download PDF

10. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

Author

Gerson, James N., Handorf, Elizabeth, Villa, Diego, Gerrie, Alina S., Chapani, Parv, Li, Shaoying, Medeiros, L. Jeffrey, Wang, Michael, Cohen, Jonathon B., Churnetski, Michael, Hill, Brian T., Sawalha, Yazeed, Hernandez-Ilizaliturri, Francisco J., Kothari, Shalin, Vose, Julie M., Bast, Martin, Fenske, Timothy, Rao Gari, Swapna Narayana, Maddocks, Kami J., Bond, David, Bachanova, Veronika, Kolla, Bhaskar, Chavez, Julio, Shah, Bijal, Lansigan, Frederick, Burns, Timothy, Donovan, Alexandra M., Wagner-Johnston, Nina, Messmer, Marcus, Mehta, Amitkumar, Anderson, Jennifer K., Reddy, Nishitha, Kovach, Alexandra E., Landsburg, Daniel J., Glenn, Martha, Inwards, David J., Ristow, Kay, Karmali, Reem, Kaplan, Jason B., Caimi, Paolo F., Rajguru, Saurabh, Evens, Andrew, Klein, Andreas, Umyarova, Elvira, Pulluri, Bhargavi, Amengual, Jennifer E., Lue, Jennifer K., Diefenbach, Catherine, Fisher, Richard I., and Barta, Stefan K.

Published
2023
Full Text
View/download PDF

13. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19:CCC19 Governance, Protocol, and Quality Assurance

Author

Abidi, Maheen, Aboulafia, David M, Accordino, Melissa K, Acoba, Jared D, Ahluwalia, Manmeet S, Ahmad, Syed A, Ajmera, Archana, Alimohamed, Saif I, Altman, Jessica, Angevine, Anne H, Bakouny, Ziad, Bar, Michael H, Bardia, Aditya, Barnholtz-Sloan, Jill S, Barrow McCollough, Briana, Bashir, Babar, Batist, Gerald, Bekaii-Saab, Tanios S, Berg, Stephanie, Bernicker, Eric H, Bhutani, Divaya, Bilen, Mehmet A, Bindal, Poorva, Bishnoi, Rohit, Blau, Sibel, Bohachek, Pamela, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bouganim, Nathaniel, Bowles, Daniel W, Busser, Fiona J, Butt, Omar, Cabal, Angelo, Cabalona, Wilhelmina D, Cabebe, Elwyn C, Caimi, Paolo, Campian, Jian L, Carducci, Theresa M, Chen, James L, Cheng, Alex, Chism, David D, Choueiri, Toni K, Clark, Melanie J, Clement, Jessica M, Connors, Jean M, Cook, Erin, Curran, Catherine R, Daher, Ahmad, Dailey, Mark E, Davis, Elizabeth J, Dawsey, Scott J, Deeken, John F, Del Prete, Salvatore A, Demetri, George D, Desai, Aakash, Doroshow, Deborah B, Durbin, Eric B, Egan, Pamela C, Elias, Rawad, Elkrief, Arielle, Elms, Destry J, Elshoury, Amro, Faller, Bryan, Farmakiotis, Dimitrios, Fecher, Leslie A, Feldman, Lawrence E, Ferrario, Cristiano, Fiala, Mark A, Flora, Daniel B, French, Benjamin, Friese, Christopher R, Fu, Julie C, Gadgeel, Shirish M, Gainor, Justin, Galsky, Matthew D, Gantt, Gerald, Garcia, Jorge A, Gartrell, Benjamin A, Gatti-Mays, Margaret E, Gill, David M, Gillaspie, Erin A, Giordano, Antonio, Glace, Mary Grace, Glover, Michael J, Goel, Sanjay, Graber, Jerome J, Griffiths, Elizabeth A, Grivas, Petros, Grover, Punita, Gulati, Anthony P, Gulati, Shuchi, Gupta, Shilpa, Gurley, Michael, Hafez, Navid, Halabi, Susan, Halfdanarson, Thorvardur R, Halmos, Balazs, Hausrath, Daniel J, and Hawley, Jessica E

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biological Sciences, Clinical Research, Cancer, COVID-19, COVID-19 Testing, Data Accuracy, Electronic Health Records, Humans, Neoplasms, Quality Improvement, SARS-CoV-2, COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org, COVID-19 and Cancer Consortium, Neurosciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments.

Published
2020

14. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Kuderer, Nicole M, Choueiri, Toni K, Shah, Dimpy P, Shyr, Yu, Rubinstein, Samuel M, Rivera, Donna R, Shete, Sanjay, Hsu, Chih-Yuan, Desai, Aakash, de Lima Lopes, Gilberto, Grivas, Petros, Painter, Corrie A, Peters, Solange, Thompson, Michael A, Bakouny, Ziad, Batist, Gerald, Bekaii-Saab, Tanios, Bilen, Mehmet A, Bouganim, Nathaniel, Larroya, Mateo Bover, Castellano, Daniel, Del Prete, Salvatore A, Doroshow, Deborah B, Egan, Pamela C, Elkrief, Arielle, Farmakiotis, Dimitrios, Flora, Daniel, Galsky, Matthew D, Glover, Michael J, Griffiths, Elizabeth A, Gulati, Anthony P, Gupta, Shilpa, Hafez, Navid, Halfdanarson, Thorvardur R, Hawley, Jessica E, Hsu, Emily, Kasi, Anup, Khaki, Ali R, Lemmon, Christopher A, Lewis, Colleen, Logan, Barbara, Masters, Tyler, McKay, Rana R, Mesa, Ruben A, Morgans, Alicia K, Mulcahy, Mary F, Panagiotou, Orestis A, Peddi, Prakash, Pennell, Nathan A, Reynolds, Kerry, Rosen, Lane R, Rosovsky, Rachel, Salazar, Mary, Schmidt, Andrew, Shah, Sumit A, Shaya, Justin A, Steinharter, John, Stockerl-Goldstein, Keith E, Subbiah, Suki, Vinh, Donald C, Wehbe, Firas H, Weissmann, Lisa B, Wu, Julie Tsu-Yu, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Yeh, Albert, Yu, Peter P, Zhou, Alice Y, Zubiri, Leyre, Mishra, Sanjay, Lyman, Gary H, Rini, Brian I, Warner, Jeremy L, Consortium, COVID-19 and Cancer, Abidi, Maheen, Acoba, Jared D, Agarwal, Neeraj, Ahmad, Syed, Ajmera, Archana, Altman, Jessica, Angevine, Anne H, Azad, Nilo, Bar, Michael H, Bardia, Aditya, Barnholtz-Sloan, Jill, Barrow, Briana, Bashir, Babar, Belenkaya, Rimma, Berg, Stephanie, Bernicker, Eric H, Bestvina, Christine, Bishnoi, Rohit, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bowles, Daniel W, Busser, Fiona, Cabal, Angelo, Caimi, Paolo, and Carducci, Theresa

Subjects
Biomedical and Clinical Sciences, Health Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Aging, Prevention, Cancer, Lung, Good Health and Well Being, Aged, Antiviral Agents, Azithromycin, Betacoronavirus, COVID-19, Cause of Death, Comorbidity, Coronavirus Infections, Databases, Factual, Female, Humans, Hydroxychloroquine, Male, Middle Aged, Neoplasms, Pandemics, Pneumonia, Viral, Prognosis, Risk Factors, SARS-CoV-2, COVID-19 Drug Treatment, COVID-19 and Cancer Consortium, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundData on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.MethodsIn this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.FindingsOf 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57-76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1·84, 95% CI 1·53-2·21), male sex (1·63, 1·07-2·48), smoking status (former smoker vs never smoked: 1·60, 1·03-2·47), number of comorbidities (two vs none: 4·50, 1·33-15·28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3·89, 2·11-7·18), active cancer (progressing vs remission: 5·20, 2·77-9·77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2·93, 1·79-4·79; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0·24, 0·07-0·84) or the US-Midwest (0·50, 0·28-0·90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.InterpretationAmong patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments.FundingAmerican Cancer Society, National Institutes of Health, and Hope Foundation for Cancer Research.

Published
2020

16. Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma

Author

Hill, Brian T, Nastoupil, Loretta, Winter, Allison M, Becnel, Melody R, Cerhan, James R, Habermann, Thomas M, Link, Brian K, Maurer, Matthew J, Fakhri, Bita, Reddy, Prathima, Smith, Stephen D, Mukhija, Dhruvika, Jagadeesh, Deepa, Desai, Amrita, Alderuccio, Juan Pablo, Lossos, Izidore S, Mehra, Pooja, Portell, Craig A, Goldman, Max L, Calzada, Oscar, Cohen, Jonathon B, Hussain, Mohammad J, Ghosh, Nilanjan, Caimi, Paolo, Tiutan, Timothy, Martin, Peter, Kodali, Abhigna, Evens, Andrew M, and Kahl, Brad S

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Cancer, Rare Diseases, Clinical Research, Lymphoma, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Female, Humans, Lymphoma, Follicular, Maintenance Chemotherapy, Male, Middle Aged, Prednisone, Retrospective Studies, Rituximab, Survival Rate, Vincristine, follicular lymphoma, bendamustine, rituximab, maintenance, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL, resulting in disparate practice patterns. Prospective trials have shown benefit of MR after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or R-CVP (rituximab, cyclophosphamide, vincristine, prednisone), yet recent data from the GALLIUM study comparing outcomes of patients treated with chemotherapy with R or obinutuzumab (G) showed higher than anticipated fatal adverse events with BR/BG. In order to assess the efficacy and tolerability of MR after BR, we retrospectively collected data on 640 newly diagnosed patients treated with FL. We found that patients who achieved partial remission (PR) after ≥4 cycles of BR had improved duration of response (DOR) with MR vs. no maintenance, whereas those in complete remission did not. These findings were confirmed in a validation cohort. In the entire study population, the known fatal adverse event rate after BR was 2·5% and did not significantly differ in those receiving MR versus no maintenance. [Correction added on 14 January 2019, after online publication: The preceding sentence has been corrected in this current version.] Within the limitations inherent to retrospective analysis, these data suggest that FL patients with a PR to BR experience prolongation of remission with MR with an acceptable safety profile.

Published
2019

19. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

Author

Schuster, Michael, Zijlstra, Josée, Casasnovas, Rene-Olivier, Vermaat, Joost S.P, Kalakonda, Nagesh, Goy, Andre, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, De la Cruz, Fatima, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Follows, George, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros, Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Corona, Kelly, Chamoun, Kamal, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Canales, Miguel, and Maerevoet, Marie

Published
2022
Full Text
View/download PDF

21. Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice.

Author

Grégoire, Céline, Coutinho de Oliveira, Beatriz, Caimi, Paolo F., Caers, Jo, and Melenhorst, Jan Joseph

Subjects
CHIMERIC antigen receptors, T cells, MULTIPLE myeloma, ACUTE leukemia, TREATMENT failure
Abstract

Summary: Autologous chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment of lymphoid malignancies, leading to the approval of CD19‐CAR T cells for B‐cell lymphomas and acute leukaemia, and more recently, B‐cell maturation antigen‐CAR T cells for multiple myeloma. The long‐term follow‐up of patients treated in the early clinical trials demonstrates the possibility for long‐term remission, suggesting a cure. This is associated with a low incidence of significant long‐term side effects and a rapid improvement in the quality of life for responders. In contrast, other types of immunotherapies require prolonged treatments or carry the risk of long‐term side effects impairing the quality of life. Despite impressive results, some patients still experience treatment failure or ultimately relapse, underscoring the imperative to improve CAR T‐cell therapies and gain a better understanding of their determinants of efficacy to maximize positive outcomes. While the next‐generation of CAR T cells will undoubtingly be more potent, there are already opportunities for optimization when utilizing the currently available CAR T cells. This review article aims to summarize the current evidence from clinical, translational and fundamental research, providing clinicians with insights to enhance their understanding and use of CAR T cells. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Author

Orellana-Noia, Victor Manuel, Reed, Daniel R., McCook, Ashley Alesia, Sen, Jeremy Michael, Barlow, Christian M., Malecek, Mary-Kate, Watkins, Marcus, Kahl, Brad S., Spinner, Michael A., Advani, Ranjana, Voorhees, Timothy J., Snow, Anson, Grover, Natalie Sophia, Ayers, Amy, Romancik, Jason, Liu, Yuxin, Huntington, Scott F., Chavez, Julio C., Saeed, Hayder, Lazaryan, Aleksandr, Raghunathan, Vikram, Spurgeon, Stephen E., Ollila, Thomas A., Del Prete, Christopher, Olszewski, Adam, Ayers, Emily C., Landsburg, Daniel J., Echalier, Benjamin, Lee, Jun, Kamdar, Manali, Caimi, Paolo F., Fu, Timothy, Liu, Jieqi, David, Kevin A., Alharthy, Hanan, Law, Jennie, Karmali, Reem, Shah, Harsh, Stephens, Deborah M., Major, Ajay, Rojek, Alexandra E., Smith, Sonali M., Yellala, Amulya, Kallam, Avyakta, Nakhoda, Shazi, Khan, Nadia, Sohail, Mohammad Ahsan, Hill, Brian T., Barrett-Campbell, Odeth, Lansigan, Frederick, Switchenko, Jeffrey, Cohen, Jonathon, and Portell, Craig A.

Published
2022
Full Text
View/download PDF

23. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

Author

Casasnovas, Rene-Olivier, Follows, George, Zijlstra, Josee M., Vermaat, Joost S.P., Kalakonda, Nagesh, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fatima De, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo F., Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Chamoun, Kamal, Shah, Jatin, Canales, Miguel, Maerevoet, Marie, Shacham, Sharon, Kauffman, Michael G., and Goy, Andre

Published
2022
Full Text
View/download PDF

24. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes.

Author

Brammer, Jonathan, Chihara, Dai, Poon, L, Caimi, Paolo, de Lima, Marcos, Ledesma, Celina, Rondon, Gabriela, Ciurea, Stefan, Nieto, Yago, Fanale, Michelle, Dabaja, Bouthaina, Maziarz, Richard, Champlin, Richard, Hosing, Chitra, and Oki, Yasuhiro

Subjects
Extranodal natural killer/T-cell lymphoma, SMILE, advanced stage, refractory disease, stem cell transplant, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cohort Studies, Female, Humans, Lymphoma, Male, Middle Aged, Natural Killer T-Cells, Neoplasm Recurrence, Local, Prognosis, Stem Cell Transplantation, Young Adult
Abstract

BACKGROUND: Extra-Nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5-10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year. Patients with advanced stage III/IV ENKL and relapsed refractory ENKL have a poor prognosis even despite aggressive therapy and stem cell transplantation (SCT). We conducted a review of the management of 37 patients with advanced-stage and relapsed/refractory ENKL in a predominantly non-Asian cohort evaluating both chemotherapy and SCT outcomes. PATIENTS AND METHODS: We evaluated clinical outcomes in all patients treated for advanced stage III/IV or relapsed/refractory ENKL at MD Anderson cancer center between 2000-2014. Next, we collected stem cell transplant data from four transplant institutions to further evaluate outcomes of both allogeneic (allo-SCT) and autologous (auto-SCT) stem cell transplantation in ENKL. RESULTS: OS and PFS were 73% and 45% at one year, and 30% and 19% at 3-years, respectively. SMILE chemotherapy was more effective in maintaining a CR compared to CHOP (83% vs 17%). Only achievement of CR was prognostic for OS (HR 0.245, p=0.002) and PFS (HR 0.072, p) CONCLUSION: Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients.

Published
2018

25. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

Author

Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., and Shouse, Geoffrey

Published
2022
Full Text
View/download PDF

27. Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP).

Author

Till, Brian G., primary, Jacobson, Caron Alyce, additional, Palomba, Maria Lia, additional, Abramson, Jeremy S., additional, Arnason, Jon, additional, Locke, Frederick L, additional, Caimi, Paolo Fabrizio, additional, Grover, Natalie Sophia, additional, Karmali, Reem, additional, Suh, Hyung C., additional, Schuster, Stephen J., additional, Gharibo, Mecide Meric, additional, Balint, Catherine, additional, Rakhmawati, Trias, additional, Jude, Veronica, additional, and Nastoupil, Loretta J., additional

Published
2024
Full Text
View/download PDF

28. Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy

Author

Tarantelli, Chiara, primary, Wald, David, additional, Munz, Nicolas, additional, Spriano, Filippo, additional, Bruscaggin, Alessio, additional, Cannas, Eleonora, additional, Cascione, Luciano, additional, Gaudio, Eugenio, additional, Arribas, Alberto J., additional, Manjappa, Shivaprasad, additional, Golino, Gaetanina, additional, Scalise, Lorenzo, additional, Cacciapuoti, Maria Teresa, additional, Zucca, Emanuele, additional, Stathis, Anastasios, additional, Inghirami, Giorgio, additional, Van Berkel, Patrick H., additional, Rossi, Davide, additional, Caimi, Paolo F., additional, Zammarchi, Francesca, additional, and Bertoni, Francesco, additional

Published
2024
Full Text
View/download PDF

30. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Author

Davids, Matthew S., O'Connor, Owen A., Jurczak, Wojciech, Samaniego, Felipe, Fenske, Timothy S., Zinzani, Pier Luigi, Patel, Manish R., Ghosh, Nilanjan, Cheson, Bruce D., Derenzini, Enrico, Brander, Danielle M., Reeves, James A., Knopińska-Posłuszny, Wanda, Allan, John N., Phillips, Tycel, Caimi, Paolo F., Lech-Maranda, Ewa, Burke, John M., Agajanian, Richy, Pettengell, Ruth, Leslie, Lori A., Cheah, Chan Y., Fonseca, Gustavo, Essell, James, Chavez, Julio C., Pagel, John M., Sharman, Jeff P., Hsu, Yanzhi, Miskin, Hari P., Sportelli, Peter, Weiss, Michael S., and Flinn, Ian W.

Published
2021
Full Text
View/download PDF

32. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis

Author

Alderuccio, Juan Pablo, Olszewski, Adam J., Evens, Andrew M., Collins, Graham P., Danilov, Alexey V., Bower, Mark, Jagadeesh, Deepa, Zhu, Catherine, Sperling, Amy, Kim, Seo-Hyun, Vaca, Ryan, Wei, Catherine, Sundaram, Suchitra, Reddy, Nishitha, Dalla Pria, Alessia, D'Angelo, Christopher, Farooq, Umar, Bond, David A., Berg, Stephanie, Churnetski, Michael C., Godara, Amandeep, Khan, Nadia, Choi, Yun Kyong, Kassam, Shireen, Yazdy, Maryam, Rabinovich, Emma, Post, Frank A., Varma, Gaurav, Karmali, Reem, Burkart, Madelyn, Martin, Peter, Ren, Albert, Chauhan, Ayushi, Diefenbach, Catherine, Straker-Edwards, Allandria, Klein, Andreas, Blum, Kristie A., Boughan, Kirsten Marie, Mian, Agrima, Haverkos, Bradley M., Orellana-Noia, Victor M., Kenkre, Vaishalee P., Zayac, Adam, Maliske, Seth M., Epperla, Narendranath, Caimi, Paolo, Smith, Scott E., Kamdar, Manali, Venugopal, Parameswaran, Feldman, Tatyana A., Rector, Daniel, Smith, Stephen D., Stadnik, Andrzej, Portell, Craig A., Lin, Yong, Naik, Seema, Montoto, Silvia, Lossos, Izidore S., and Cwynarski, Kate

Published
2021
Full Text
View/download PDF

37. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Author

Evens, Andrew M., Danilov, Alexey, Jagadeesh, Deepa, Sperling, Amy, Kim, Seo-Hyun, Vaca, Ryan, Wei, Catherine, Rector, Daniel, Sundaram, Suchitra, Reddy, Nishitha, Lin, Yong, Farooq, Umar, D'Angelo, Christopher, Bond, David A., Berg, Stephanie, Churnetski, Michael C., Godara, Amandeep, Khan, Nadia, Choi, Yun Kyong, Yazdy, Maryam, Rabinovich, Emma, Varma, Gaurav, Karmali, Reem, Mian, Agrima, Savani, Malvi, Burkart, Madelyn, Martin, Peter, Ren, Albert, Chauhan, Ayushi, Diefenbach, Catherine, Straker-Edwards, Allandria, Klein, Andreas K., Blum, Kristie A., Boughan, Kirsten Marie, Smith, Scott E., Haverkos, Brad M., Orellana-Noia, Victor M., Kenkre, Vaishalee P., Zayac, Adam, Ramdial, Jeremy, Maliske, Seth M., Epperla, Narendranath, Venugopal, Parameswaran, Feldman, Tatyana A., Smith, Stephen D., Stadnik, Andrzej, David, Kevin A., Naik, Seema, Lossos, Izidore S., Lunning, Matthew A., Caimi, Paolo, Kamdar, Manali, Palmisiano, Neil, Bachanova, Veronika, Portell, Craig A., Phillips, Tycel, Olszewski, Adam J., and Alderuccio, Juan Pablo

Published
2021
Full Text
View/download PDF

39. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Abidi, Maheen, Acoba, Jared D., Agarwal, Neeraj, Ahmad, Syed, Ajmera, Archana, Altman, Jessica, Angevine, Anne H., Azad, Nilo, Bar, Michael H., Bardia, Aditya, Barnholtz-Sloan, Jill, Barrow, Briana, Bashir, Babar, Belenkaya, Rimma, Berg, Stephanie, Bernicker, Eric H., Bestvina, Christine, Bishnoi, Rohit, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bowles, Daniel W., Busser, Fiona, Cabal, Angelo, Caimi, Paolo, Carducci, Theresa, Casulo, Carla, Chen, James L., Clement, Jessica M, Chism, David, Cook, Erin, Curran, Catherine, Daher, Ahmad, Dailey, Mark, Dahiya, Saurabh, Deeken, John, Demetri, George D., DiLullo, Sandy, Duma, Narjust, Elias, Rawad, Faller, Bryan, Fecher, Leslie A., Feldman, Lawrence E., Friese, Christopher R., Fu, Paul, Fu, Julie, Futreal, Andy, Gainor, Justin, Garcia, Jorge, Gill, David M., Gillaspie, Erin A., Giordano, Antonio, Glace, (Mary) Grace, Grothey, Axel, Gulati, Shuchi, Gurley, Michael, Halmos, Balazs, Herbst, Roy, Hershman, Dawn, Hoskins, Kent, Jain, Rohit K., Jabbour, Salma, Jha, Alokkumar, Johnson, Douglas B., Joshi, Monika, Kelleher, Kaitlin, Kharofa, Jordan, Khan, Hina, Knoble, Jeanna, Koshkin, Vadim S., Kulkarni, Amit A., Lammers, Philip E., Leighton, John C., Jr, Lewis, Mark A., Li, Xuanyi, Li, Ang, Lo, K.M. Steve, Loaiza-Bonilla, Arturo, LoRusso, Patricia, Low, Clarke A., Lustberg, Maryam B., Mahadevan, Daruka, Mansoor, Abdul-Hai, Marcum, Michelle, Markham, Merry Jennifer, Handy Marshall, Catherine, Mashru, Sandeep H., Matar, Sara, McNair, Christopher, McWeeney, Shannon, Mehnert, Janice M., Menendez, Alvaro, Menon, Harry, Messmer, Marcus, Monahan, Ryan, Mushtaq, Sarah, Nagaraj, Gayathri, Nagle, Sarah, Naidoo, Jarushka, Nakayama, John M., Narayan, Vikram, Nelson, Heather H., Nemecek, Eneida R., Nguyen, Ryan, Nuzzo, Pier Vitale, Oberstein, Paul E., Olszewski, Adam J., Owenby, Susie, Pasquinelli, Mary M., Philip, John, Prabhakaran, Sabitha, Puc, Matthew, Ramirez, Amelie, Rathmann, Joerg, Revankar, Sanjay G., Rho, Young Soo, Rhodes, Terence D., Rice, Robert L., Riely, Gregory J., Riess, Jonathan, Rink, Cameron, Robilotti, Elizabeth V., Rosenstein, Lori, Routy, Bertrand, Rovito, Marc A., Saif, M. Wasif, Sanyal, Amit, Schapira, Lidia, Schwartz, Candice, Serrano, Oscar, Shah, Mansi, Shah, Chintan, Shaw, Grace, Shergill, Ardaman, Shouse, Geoffrey, Soares, Heloisa P., Solorzano, Carmen C., Srivastava, Pramod K., Stauffer, Karen, Stover, Daniel G., Stratton, Jamie, Stratton, Catherine, Subbiah, Vivek, Tamimi, Rulla, Tannir, Nizar M., Topaloglu, Umit, Van Allen, Eli, Van Loon, Susan, Vega-Luna, Karen, Venepalli, Neeta, Verma, Amit K., Vikas, Praveen, Wall, Sarah, Weinstein, Paul L., Weiss, Matthias, Wise-Draper, Trisha, Wood, William A., Xu, Wenxin (Vincent), Yackzan, Susan, Zacks, Rosemary, Zhang, Tian, Zimmer, Andrea J., West, Jack, Kuderer, Nicole M, Choueiri, Toni K, Shah, Dimpy P, Shyr, Yu, Rubinstein, Samuel M, Rivera, Donna R, Shete, Sanjay, Hsu, Chih-Yuan, Desai, Aakash, de Lima Lopes, Gilberto, Jr, Grivas, Petros, Painter, Corrie A, Peters, Solange, Thompson, Michael A, Bakouny, Ziad, Batist, Gerald, Bekaii-Saab, Tanios, Bilen, Mehmet A, Bouganim, Nathaniel, Larroya, Mateo Bover, Castellano, Daniel, Del Prete, Salvatore A, Doroshow, Deborah B, Egan, Pamela C, Elkrief, Arielle, Farmakiotis, Dimitrios, Flora, Daniel, Galsky, Matthew D, Glover, Michael J, Griffiths, Elizabeth A, Gulati, Anthony P, Gupta, Shilpa, Hafez, Navid, Halfdanarson, Thorvardur R, Hawley, Jessica E, Hsu, Emily, Kasi, Anup, Khaki, Ali R, Lemmon, Christopher A, Lewis, Colleen, Logan, Barbara, Masters, Tyler, McKay, Rana R, Mesa, Ruben A, Morgans, Alicia K, Mulcahy, Mary F, Panagiotou, Orestis A, Peddi, Prakash, Pennell, Nathan A, Reynolds, Kerry, Rosen, Lane R, Rosovsky, Rachel, Salazar, Mary, Schmidt, Andrew, Shah, Sumit A, Shaya, Justin A, Steinharter, John, Stockerl-Goldstein, Keith E, Subbiah, Suki, Vinh, Donald C, Wehbe, Firas H, Weissmann, Lisa B, Wu, Julie Tsu-Yu, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Yeh, Albert, Yu, Peter P, Zhou, Alice Y, Zubiri, Leyre, Mishra, Sanjay, Lyman, Gary H, Rini, Brian I, and Warner, Jeremy L

Published
2020
Full Text
View/download PDF

40. Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities – a Multicenter Retrospective Analysis

Author

Bajwa, Amneet, primary, Zhao, Qiuhong, additional, Geer, Marcus J., additional, Mian, Agrima, additional, Lin, Chenyu, additional, Frame, David, additional, Westholder, James, additional, Tossey, Dr. Justin, additional, Ghosh, Monalisa, additional, Galal, Ahmed, additional, Ahmed, Nausheen, additional, Maakaron, Joseph E., additional, Denlinger, Nathan, additional, de Lima, Marcos, additional, Epperla, Narendranath, additional, Caimi, Paolo, additional, and Voorhees, Timothy, additional

Published
2024
Full Text
View/download PDF

41. Outcomes in Patients (pts) with R/R Large B-Cell Lymphoma (LBCL) Who Received Nonconforming Product (NCP) to Commercial Release of Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Author

Caimi, Paolo, primary, Schuster, Stephen J., additional, Nastoupil, Loretta J., additional, Grover, Natalie, additional, Hoda, Daanish, additional, Karmali, Reem, additional, Hu, Bei, additional, Locke, Frederick L., additional, McCarthy, Philip L., additional, Palomba, M. Lia, additional, Suh, Hyung C., additional, Pasquini, Marcelo C., additional, Balint, Catherine, additional, Bernasconi, David, additional, Jude, Veronica, additional, Gharibo, Mecide, additional, and Jacobson, Caron, additional

Published
2024
Full Text
View/download PDF

42. Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) Treated with CAR T-Cell Therapies.

Author

Mian, Agrima, primary, Dima, Danai, additional, Hamilton, Betty K., additional, Winter, Allison, additional, Khouri, Jack, additional, Williams, Louis, additional, Raza, Shahzad, additional, Jagadeesh, Deepa, additional, Gerds, Aaron T., additional, Dean, Robert M., additional, Sobecks, Ronald M., additional, Kalaycio, Matt E., additional, Brunstein, Claudio G., additional, Sauter, Craig S, additional, Anwer, Faiz, additional, Hill, Brian T., additional, and Caimi, Paolo, additional

Published
2024
Full Text
View/download PDF

43. Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy

Author

Crombie, Jennifer L., primary, Graff, Tara, additional, Falchi, Lorenzo, additional, Karimi, Yasmin H., additional, Bannerji, Rajat, additional, Nastoupil, Loretta J, additional, Thieblemont, Catherine, additional, Ursu, Renata, additional, Bartlett, Nancy L., additional, Nachar, Victoria R, additional, Weiss, Jonathan, additional, Osterson, Jane, additional, Patel, Krish, additional, Brody, Joshua D., additional, Abramson, Jeremy S, additional, Lunning, Matthew A, additional, Shah, Nirav N., additional, Ayed, Ayed, additional, Kamdar, Manali, additional, Parsons, Benjamin M., additional, Caimi, Paolo, additional, Flynn, Ian W., additional, Herrera, Alex F., additional, Sharman, Jeff P., additional, McKenna, Marshall, additional, Armand, Philippe, additional, Kahl, Brad S., additional, Smith, Sonali M, additional, Zelenetz, Andrew D, additional, Budde, Lihua E, additional, Hutchings, Martin, additional, Phillips, Tycel J., additional, and Dickinson, Michael, additional

Published
2024
Full Text
View/download PDF

44. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Author

Hamadani, Mehdi, primary, Spira, Alexander, additional, Zhou, Xiaolei, additional, Liao, Laura, additional, Chen, Lei, additional, Radford, John, additional, Ai, Weiyun, additional, Solh, Melhem, additional, Ardeshna, Kirit M., additional, Hess, Brian, additional, Caimi, Paolo F., additional, Stathis, Anastasios, additional, Carlo-Stella, Carmelo, additional, Alderuccio, Juan Pablo, additional, Kahl, Brad, additional, Wang, Ying, additional, Qin, Yajuan, additional, Xu, Zhiying Cindy, additional, and Zinzani, Pier Luigi, additional

Published
2024
Full Text
View/download PDF

45. Supplementary Table S4 from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., primary, Hamadani, Mehdi, primary, Nachiappan, Muthiah, primary, Leslom, Salman, primary, Kahl, Brad S., primary, Ai, Weiyun Z., primary, Radford, John, primary, Solh, Melhem, primary, Ardeshna, Kirit M., primary, Hess, Brian T., primary, Lunning, Matthew A., primary, Zinzani, Pier Luigi, primary, Stathis, Anastasios, primary, Carlo-Stella, Carmelo, primary, Lossos, Izidore S., primary, Caimi, Paolo F., primary, Han, Sunwoo, primary, Yang, Fei, primary, Kuker, Russ A., primary, and Moskowitz, Craig H., primary

Published
2024
Full Text
View/download PDF

46. Data from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., primary, Hamadani, Mehdi, primary, Nachiappan, Muthiah, primary, Leslom, Salman, primary, Kahl, Brad S., primary, Ai, Weiyun Z., primary, Radford, John, primary, Solh, Melhem, primary, Ardeshna, Kirit M., primary, Hess, Brian T., primary, Lunning, Matthew A., primary, Zinzani, Pier Luigi, primary, Stathis, Anastasios, primary, Carlo-Stella, Carmelo, primary, Lossos, Izidore S., primary, Caimi, Paolo F., primary, Han, Sunwoo, primary, Yang, Fei, primary, Kuker, Russ A., primary, and Moskowitz, Craig H., primary

Published
2024
Full Text
View/download PDF

47. Supplementary Figure S2 from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., primary, Hamadani, Mehdi, primary, Nachiappan, Muthiah, primary, Leslom, Salman, primary, Kahl, Brad S., primary, Ai, Weiyun Z., primary, Radford, John, primary, Solh, Melhem, primary, Ardeshna, Kirit M., primary, Hess, Brian T., primary, Lunning, Matthew A., primary, Zinzani, Pier Luigi, primary, Stathis, Anastasios, primary, Carlo-Stella, Carmelo, primary, Lossos, Izidore S., primary, Caimi, Paolo F., primary, Han, Sunwoo, primary, Yang, Fei, primary, Kuker, Russ A., primary, and Moskowitz, Craig H., primary

Published
2024
Full Text
View/download PDF

49. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

Author

Shapiro, Geoffrey I., LoRusso, Patricia, Dowlati, Afshin, T. Do, Khanh, Jacobson, Caron A., Vaishampayan, Ulka, Weise, Amy, Caimi, Paolo F., Eder, Joseph Paul, French, Christopher A., Labriola-Tompkins, Emily, Boisserie, Frédéric, Pierceall, William E., Zhi, Jianguo, Passe, Sharon, DeMario, Mark, Kornacker, Martin, and Armand, Philippe

Published
2021
Full Text
View/download PDF

50. The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral Center

Author

Nakayama, John, Wang, Gi-Ming, Cioffi, Gino, Waite, Kristin A., Patil, Nirav, Kyasaram, Ravi Kumar, Shanahan, John, Caimi, Paolo, and Barnholtz-Sloan, Jill S.

Subjects
Oncology, Experimental -- Analysis, Epidemics -- Analysis, Radiation -- Analysis, Cancer -- Analysis -- Research, Health
Abstract

OBJECTIVES: COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic. METHODS: This case-controlled trial evaluated more than 345,000 oncologic clinic, lab, and radiation appointments from January 1, 2019, through December 31, 2020, and surgery appointments from January 1, 2019, through October 31, 2020. All patients at the Seidman Cancer Center with a cancer diagnosis based on a comprehensive list of 2178 International Classification of Diseases, Ninth Edition (ICD-9) and ICD-10 codes were included in the analysis. Subgroup analyses based on age, race, and sex were also performed. RESULTS: Clinic, lab, and surgical visit cancellations increased by 4.20% (P CONCLUSIONS: There was a large increase in cancelled oncologic care in 2020, which has implications for delayed diagnosis and treatment. This was especially true for patients older than 65 years and for women. These delays could result in patients presenting with more advanced disease, complicating morbidities, and ultimately worse long-term outcomes., Introduction The COVID-19 pandemic created an unprecedented situation pitting the urgent need to appropriately treat patients with cancer against the unknown level of risk of subjecting patients to immunosuppressive therapies [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results